Axiom Bio

Building the Translational Intelligence Layer for Drug Discovery

Axiom Bio is addressing one of the most intractable and costly challenges in pharmaceutical development: the unpredictable molecular toxicity that leads to drug failures. Despite decades of reliance on animal models to predict human responses, over 90% of drugs that clear preclinical animal testing ultimately fail in human clinical trials. This failure rate is a staggering bottleneck, contributing to astronomical costs, delayed treatments, and, most critically, risks to patient safety. Animal models, while historically the gold standard, are inherently limited by species differences—biological responses in animals often do not accurately reflect human physiology or toxicity pathways. This disconnect results in late-stage clinical trial failures that could have been anticipated with better translational models.

Axiom Bio is pioneering a transformative approach that leverages artificial intelligence integrated with advanced human-relevant biological systems to predict drug toxicity more accurately and earlier in the development pipeline. Their proprietary platform is anchored on a 2D primary human hepatocyte system and an enhanced 2D+ multi-cell hepatic model. These liver-based systems generate multiplexed high-content biochemical and imaging data, capturing the rich complexity of human liver biology critical for assessing drug metabolism and toxicity.

The company’s AI models are trained on the world’s largest experimental-to-clinical dataset—a unique resource that bridges cellular assay results with clinical outcomes. This integration allows Axiom Bio’s platform to translate in vitro signals into meaningful predictions about human toxicity, offering a significant improvement over traditional animal testing. By providing earlier, more reliable insights into drug safety, Axiom Bio empowers pharmaceutical companies, biotech startups, and agrochemical firms to make smarter decisions, reduce late-stage failures, and ultimately accelerate the delivery of safer medicines to patients.

Founded in 2024 by Brandon White and Alex Beatson, Axiom Bio operates out of San Francisco, a hub of biotech innovation and AI development. With $15 million in seed funding from notable investors such as Amplify Partners, Dimension Capital, and Zetta Ventures, the company is well-positioned to scale its platform and expand its impact. Joining Axiom Bio means being part of an early-stage startup that sits at the critical intersection of biology and AI, working on a mission to fundamentally change how drug toxicity is understood and predicted.

A Culture of Scientific Rigor and Innovation

At Axiom Bio, the culture is deeply rooted in a commitment to scientific rigor, transparency, and continuous innovation. The startup brings together a multidisciplinary team of experts in biology, computational science, machine learning, and software engineering. This collaboration across disciplines is essential to tackling the complex problem of molecular toxicity, which requires not only cutting-edge AI models but also a profound understanding of human biology and experimental design.

The company fosters an environment where ideas are rigorously tested and validated. This is reflected in their use of blinded comparisons and transparent performance benchmarks to evaluate AI predictions against real-world clinical outcomes. Such scientific diligence is critical in a field where the stakes are high—improving drug safety can save millions of lives and billions of dollars.

Innovation at Axiom Bio is not just about technology but about rethinking established drug discovery paradigms. The team is encouraged to challenge traditional reliance on animal models and explore new methodologies that combine biological complexity with computational power. Employees find themselves in a culture that values curiosity, critical thinking, and the willingness to explore uncharted scientific territory.

Moreover, the startup’s early-stage nature means that team members often wear multiple hats, collaborating closely and learning from one another. This dynamic environment rewards flexibility and initiative, offering a rare opportunity to contribute meaningfully to both scientific and product development. Transparency within the team and alignment around the mission to reduce molecular toxicity create a strong sense of shared purpose, which is vital for sustaining motivation in a challenging domain.

What You'll Actually Do

Joining Axiom Bio means contributing directly to a pioneering platform that aims to reshape drug discovery by improving the prediction of human toxicity. Roles at the company are intellectually demanding and impactful, requiring a blend of technical expertise and biological insight. Depending on your specialization, your day-to-day responsibilities may include:

- Data Engineering: You will architect and maintain robust data pipelines that handle extremely large and complex datasets—millions of labeled cell images and billions of mitochondrial measurements. Reliable, scalable data infrastructure is critical to support AI training and real-time analytics. Your work ensures that research scientists and machine learning engineers have timely access to clean, well-structured data, enabling iterative model improvements and biological discovery.

- Machine Learning Research: As an ML researcher, you will spearhead the development of models that predict toxicity signatures from biological assays. This includes designing end-to-end machine learning architectures capable of integrating heterogeneous data sources—from imaging to biochemical assays—and uncovering subtle chemistry-biology relationships. Your work will directly replace or augment traditional lab experiments, with the goal of identifying toxicological risks ahead of costly clinical failures.

- Computational Science: This role involves deep analysis of biological data, such as mass spectrometry and high-content imaging, to extract meaningful patterns related to drug effects. You will develop software tools and scalable computational workflows that enable both AI systems and human experts to interpret complex biological phenomena. A strong foundation in biology is essential to translate experimental findings into models that truly reflect human physiology.

- Platform Engineering: You will build and maintain the scalable infrastructure that underpins Axiom Bio’s AI platform. This includes ensuring the reliability, security, and performance of enterprise-grade applications deployed in collaboration with pharmaceutical partners. Your work facilitates seamless integration of AI predictions into customer workflows, enabling real-world impact and adoption.

Regardless of your function, you will be part of a team that is actively reducing dependence on animal testing and pioneering AI-driven, human-relevant approaches. The complexity and novelty of the problem space demand creativity, technical excellence, and a willingness to engage deeply with both biological and computational challenges.

Compensation & Benefits

Axiom Bio’s recent $15 million seed funding round underscores strong investor confidence and provides a solid financial foundation for growth and innovation. While the company has not publicly disclosed specific salary figures, compensation for roles combining AI and biotech expertise in San Francisco typically reflects the competitive market for top talent.

Candidates can reasonably expect base salaries aligned with industry norms for early-stage AI biotech startups, potentially ranging from approximately $115,000 to over $200,000 annually, depending on experience and role seniority. Equity is a fundamental component of the compensation package, offering employees the opportunity to benefit from the company’s long-term success and growth trajectory.

Benefits at Axiom Bio are designed to attract and retain high-caliber professionals in a competitive landscape. These generally include comprehensive health insurance coverage—medical, dental, and vision—and may extend to other standard startup perks such as flexible time off, professional development support, and wellness programs. The company’s San Francisco headquarters supports an in-person collaborative environment, which can foster stronger team cohesion and faster problem-solving but may require relocation or commute considerations for some candidates.

As an early-stage startup, Axiom Bio offers the unique advantage of being part of a high-impact mission from the ground up. Employees have a direct line of sight into how their work influences product direction and company growth, making the total compensation package more than just financial—it is an investment in a potentially transformative biotechnological future.

The Interview Process

Although Axiom Bio has not publicly detailed its interview process, candidates should anticipate a thorough and multi-faceted evaluation aligned with the company’s interdisciplinary and technical demands. The process typically involves:

- Technical Assessments: Expect problem-solving exercises and coding challenges relevant to your domain—whether in machine learning algorithms, data engineering pipelines, computational biology, or software development. These assessments gauge your ability to work with large, complex datasets and apply biological knowledge computationally.

- Scientific Discussions: Given the company’s focus on biology and AI integration, interviews will likely include in-depth conversations about your understanding of molecular toxicity, experimental models, and translational research. Candidates may be asked to analyze case studies or interpret biological data to demonstrate domain expertise.

- Behavioral Interviews: These sessions assess cultural fit and collaboration skills. Given the startup’s emphasis on teamwork and shared mission, candidates should be prepared to discuss how they navigate interdisciplinary environments, handle ambiguity, and contribute to fast-evolving projects.

Candidates who succeed will demonstrate not only technical proficiency but also the ability to communicate complex concepts across scientific and engineering teams. Alignment with Axiom Bio’s mission to replace animal testing with predictive AI methods is equally crucial, as this reflects the mindset needed to thrive in a company committed to challenging industry norms.

Why Join / Why Not

Why Join:

Axiom Bio offers a rare opportunity to work at the forefront of AI-driven drug discovery, addressing a problem with profound implications for human health and pharmaceutical innovation. As an early-stage startup with substantial seed funding, the company provides a dynamic environment where your contributions can have outsized impact. You will collaborate with leading experts in a culture that values scientific rigor, transparency, and technological creativity. If you are passionate about leveraging AI to solve real-world biological challenges and want to be part of a mission-driven team transforming how medicines are developed, Axiom Bio is an ideal place to grow your career.

Why Not:

Joining an early-stage startup like Axiom Bio means embracing a high degree of uncertainty and rapid change. The fast-paced environment requires adaptability and comfort with some ambiguity as processes and priorities evolve. For individuals who prefer well-established corporate structures, predictable workflows, or fully remote work options, Axiom Bio’s primarily in-office San Francisco location and startup culture may not be the best fit. Additionally, the highly specialized, technical nature of the work demands deep expertise and a strong commitment to interdisciplinary collaboration—candidates seeking less complex or broader roles might find this environment challenging.

In summary, Axiom Bio is a compelling opportunity for those eager to contribute to a pioneering solution at the nexus of AI and human biology, with the potential to redefine drug safety and accelerate the arrival of safer therapies worldwide.